Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Summary

To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.

Timeline

Start

2022-03-14

Primary completion

2024-03-01

Completion

2024-09-01

Publications

• Meng X, Yang X, Hong Y, Wang W, Zhang Z, Xia J, Chen Y, Zhou Y, Lu T, Song M, Shan Z, Wu T, Wu W, Shen L, Guan L, Ma M, Wang L, Luo X, Xin D, Ma Y, Jiang G, Qi Y, Jiang B, Zhang D, Hu B, Wu X, Peng Z, Wang F. Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11;24(1):175. doi: 10.1186/s12943-025-02376-w.

Drugs

Indications